Overview

Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD

Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of a 9-month treatment of tiotropium (SPIRIVA®) 18 mcg once daily on Health Related Quality of Life and lung function in patients with a Chronic Obstructive Pulmonary Disease.
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Tiotropium Bromide